Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis

• Sponsor: GlaxoSmithKline (Industry)
• Overall Status: Completed
• CT.gov ID: NCT03028467
• Collaborator: (none)
• Enrollment: 15
• Locations: 32
• Arms: 4
• Actual Duration (Months): 10.8
• Patients Per Site: 0.5
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

This is a randomized, double-blind, parallel group, 3 dosage level, placebo-controlled, Phase 1/2 study designed to evaluate the pharmacokinetics, safety, tolerability, and efficacy of the monoclonal antibody GSK3196165, in Japanese subjects with active moderate-severe rheumatoid arthritis (RA) despite treatment with methotrexate(MTX). The subjects will receive GSK3196165 in combination with methotrexate therapy for the 12 weeks of treatment period. Approximately 55 subjects will be screened to achieve 40 randomized subjects, so as to have approximately 10 subjects in each treatment group.

Condition or Disease	Intervention/Treatment	Phase
Arthritis, Rheumatoid	Drug: GSK3196165 Dose 1; Drug: GSK3196165 Dose 2; Drug: GSK3196165 Dose 3; Drug: Methotrexate; Drug: Placebo; Drug: Folic acid	Phase 1/Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 15 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination With Methotrexate Therapy, in Japanese Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate
• Actual Study Start Date: Jan 24, 2017
• Actual Primary Completion Date: Dec 20, 2017
• Actual Study Completion Date: Dec 20, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: GSK3196165 Dose 1 Participants will receive GSK3196165 Dose 1 weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.	Drug: GSK3196165 Dose 1; GSK3196165 is supplied as liquid and will be administered as SC injection.; Drug: Methotrexate; Methotrexate capsule/tablet 8-16 mg per week is given orally.; Drug: Folic acid; Folic acid tablet 5 mg per week is given orally.
Experimental: GSK3196165 Dose 2 Participants will receive GSK3196165 Dose 2 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.	Drug: GSK3196165 Dose 2; GSK3196165 is supplied as liquid and will be administered as SC injection.; Drug: Methotrexate; Methotrexate capsule/tablet 8-16 mg per week is given orally.; Drug: Folic acid; Folic acid tablet 5 mg per week is given orally.
Experimental: GSK3196165 Dose 3 Participants will receive GSK3196165 Dose 3 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.	Drug: GSK3196165 Dose 3; GSK3196165 is supplied as liquid and will be administered as SC injection.; Drug: Methotrexate; Methotrexate capsule/tablet 8-16 mg per week is given orally.; Drug: Folic acid; Folic acid tablet 5 mg per week is given orally.
Placebo Comparator: Placebo Participants will receive placebo weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.	Drug: Methotrexate; Methotrexate capsule/tablet 8-16 mg per week is given orally.; Drug: Placebo; Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.; Drug: Folic acid; Folic acid tablet 5 mg per week is given orally.

Outcome Measures

Primary Outcome Measures

1. Maximum Observed Concentration (Cmax) of GSK3196165 [Pre-dose on Days 1, 8, 15, 29, 57 and 71; anytime during visit on Days 3, 74, 85, 106, 127 and 155]

   Blood samples were collected at pre-dose on Days 1, 8, 15, 29, 57 and 71; and at any time during visit on Days 3, 74, 85, 106, 127 and 155. PK parameters were calculated by non-compartmental analysis using the concentration data after last dosing (Day 71). Only those participants whose parameters could be determined were analyzed. PK Population included all GSK3196165-treated participants from whom PK samples were collected and analyzed.

2. Area Under the Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC [0-t]), AUC From Time Zero Extrapolated to Infinity (AUC [0-inf]), AUC Over the Dosing Interval (AUCtau) of GSK3196165 [Pre-dose on Days 1, 8, 15, 29, 57 and 71; anytime during visit on Days 3, 74, 85, 106, 127 and 155]

   Blood samples were collected at pre-dose on Days 1, 8, 15, 29, 57 and 71; and at any time during visit on Days 3, 74, 85, 106, 127 and 155. PK parameters were calculated by non-compartmental analysis using the concentration data after last dosing (Day 71). NA indicates data was not available as geometric mean and/or 95 percent confidence interval could not be calculated when number of participant was not sufficient.

3. Time to Reach Cmax (Tmax) of GSK3196165 [Pre-dose on Days 1, 8, 15, 29, 57 and 71; anytime during visit on Days 3, 74, 85, 106, 127 and 155]

   Blood samples were collected at pre-dose on Days 1, 8, 15, 29, 57 and 71; and at any time during visit on Days 3, 74, 85, 106, 127 and 155. PK parameters were calculated by non-compartmental analysis using the concentration data after last dosing (Day 71).

4. Terminal Half-life (t1/2) of GSK3196165 [Pre-dose on Days 1, 8, 15, 29, 57 and 71; anytime during visit on Days 3, 74, 85, 106, 127 and 155.]

   Blood samples were collected at pre-dose on Days 1, 8, 15, 29, 57 and 71; and at any time during visit on Days 3, 74, 85, 106, 127 and 155. PK parameters were calculated by standard non-compartmental analysis from the concentration data after last dosing (Day 71). NA indicates data was not available as 95 percent confidence interval could not be calculated when number of participant was not sufficient.

5. Number of Participants With Any Adverse Event (AE), Serious AE (SAE) and Adverse Events of Special Interest (AESI) [Up to 22 weeks]

   An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or event associated with liver injury and impaired liver function were categorized as SAE. AESI included serious infections including serious respiratory infections and tuberculosis and opportunistic infections, neutropenia (grade 3 or 4), respiratory events, pulmonary alveolar proteinosis, hypersensitivity reactions including anaphylaxis and injection site reactions.

Secondary Outcome Measures

1. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) [Baseline and up to 22 weeks]

   Vital sign measurements including SBP and DBP were measured after 5 minutes rest before each reading. Baseline was considered as the latest pre-dose assessment. The change from Baseline is defined as the difference between the post-dose visit value and Baseline value.

2. Change From Baseline in Heart Rate (HR) [Baseline and up to 22 weeks]

   Vital sign measurements including HR was measured after 5 minutes rest before each reading. Baseline was considered as the latest pre-dose assessment. The change from Baseline is defined as the difference between the post-dose visit value and Baseline value.

3. Change From Baseline in Body Temperature [Baseline and up to 22 weeks]

   Vital sign measurements including body temperature was measured after 5 minutes rest before each reading. Baseline was considered as the latest pre-dose assessment. The change from Baseline is defined as the difference between the post-dose visit value and Baseline value.

4. Change From Baseline in Respiratory Rate [Baseline and up to 22 weeks]

   Vital sign measurements including respiratory rate was measured after 5 minutes rest before each reading. Baseline was considered as the latest pre-dose assessment. The change from Baseline is defined as the difference between the post-dose visit value and Baseline value.

5. Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings [At Week 12]

   12-Lead ECGs were taken using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and corrected QT (QTc) intervals. Number of participants with any abnormal findings in ECG recordings were summarized as clinically significant and not clinically significant. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

6. Number of Participants With Emergent Hematology Results Relative to Normal Range [Up to 22 weeks]

   Blood samples were collected to evaluate hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), erythrocytes, reticulocytes, white blood cells (WBC), total neutrophils, eosinophils, basophils, monocytes, lymphocytes, platelet count, activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, erythrocyte sedimentation rate (ESR). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose lab value category was unchanged (e.g. High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if they had values that changed 'To Low' and 'To High', so the percentages may not add to 100% in such instances.

7. Number of Participants With Emergent Clinical Chemistry Results Relative to Normal Range [Up to 22 weeks]

   Blood samples were collected to evaluate Albumin, Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Total Bilirubin, Calcium, Cholesterol, Creatine Kinase, C-Reactive protein (CRP), Creatinine, Gamma Glutamyl Transferase (GGT), Glucose, High Density Lipids (HDL), Potassium, Lactate Dehydrogenase, Low Density Lipids (LDL), Sodium, Phosphorus inorganic, Triglycerides, Total Protein and Urea. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose lab value category was unchanged (e.g. High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if they had values that changed 'To Low' and 'To High', so the percentages may not add to 100% in such instances.

8. Number of Participants With Urinalysis Dipstick Findings [Up to 22 weeks]

   Urine samples were collected for analysis of presence of glucose and protein in urine by dipstick method. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine protein and glucose can be read as negative, Trace, 1+, 2+ and 3+, indicating proportional concentrations in the urine sample

9. Number of Participants With Anti-GSK3196165 Antibody Test Results [Weeks 2, 4, 12 and 22]

   Serum samples were collected and tested for presence of antibodies that bind to GSK3196165. The presence of treatment emergent anti-drug antibodies (ADA) were determined using a GSK3196165 bridging style ADA assay with a bio-analytically determined cut point determined during assay validation. Samples taken after dosing with GSK3196165 that have a value at or above the cut-point were considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Baseline was considered as the latest pre-dose assessment. Number of participants with post-Baseline negative or positive anti-GSK3196165 antibody test results were presented.

10. Change From Baseline in Disease Activity Score for 28 Different Joints C-reactive Protein (DAS28 [CRP]) at All Indicated Timepoints [Baseline, up to Week 22]

    DAS28 (CRP) is a measure of disease activity in rheumatoid arthritis obtained by examination of 28 joints for swelling and tenderness using CRP as a blood biomarker for inflammation. Its components include: Tender/Painful Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), CRP and Patient's Global Assessment of Arthritis. DAS28 (CRP) was calculated by 0.56 (square root of TJC28)+ 0.28 (square root of SJC28)+ 0.36 (natural logarithm [CRP+1])+ (0.014*patients global assessment)+0.96. Scores ranges from 0 to infinity, where higher scores indicates high disease activity. Scores higher than 5.1 indicates high disease activity and scores lower than 2.6 indicates remission. Baseline was considered as the latest pre-dose assessment. The change from Baseline is defined as the difference between the post-dose visit value and Baseline value. Adjusted mean and standard error of adjusted mean are presented using Mixed Model for Repeated Measures.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 20 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Age: >=20 years at the time of signing informed consent - Japanese rheumatoid arthritis (RA) subjects who meets American College of Rheumatology or European League Against Rheumatism (ACR/EULAR) 2010 RA Classification Criteria

• Functional class I, II or III defined by the 1992 ACR Classification of Functional Status in RA

• Disease duration of >=12 weeks (time from onset of subject-reported symptoms of either pain or stiffness or swelling in hands, feet or wrists).

• Swollen joint count of >=4 (66-joint count) and tender joint count of >=4 (68-joint count) at screening and at Day 1

• DAS28(CRP) >=3.2 at screening

• C-Reactive Protein (CRP) >=0.5 milligrams (mg)/deciliter (dL) at screening

• Must have previously received methotrexate (MTX) (8-16 mg weekly) orally for at least 12 weeks before screening, with a stable and tolerated dose for >=4 weeks prior to Day 1

• =40 kilograms (kg) - Male or female subjects are eligible to participate so long as they meet and agree to abide by the contraceptive criteria

• Written informed consent prior to any of the screening procedures including discontinuation of prohibited medications

• Willing to continue or initiate treatment with oral folic acid (5 mg/week) and be treated during the entire study (mandatory co-medication for MTX treatment)

• Diffusing capacity of lung for carbon monoxide (DLCO) >=60% predicted; forced expiratory volume in 1 second (FEV1) >=70% predicted; forced vital capacity (FVC)

=80% predicted

• For subjects with DLCO values ≥60% to <70%, a baseline chest high-resolution computed tomography (HRCT) must be performed during the screening period, and it is recommended that the subject be reviewed by a local pulmonologist to exclude significant pre-existing respiratory disease.

• No evidence of active or latent infection with Mycobacterium tuberculosis (TB), as defined by all of the following:

• No history of active or latent TB infection irrespective of treatment status

• A negative T-spot test within 4 weeks of baseline (Day 1)

• Chest X-ray within 12 weeks of Day 1, locally read by a radiologist, with no evidence of current or previous pulmonary tuberculosis

Exclusion Criteria:

• Pregnant or lactating women

• History of other inflammatory rheumatologic or autoimmune disorders, other than Sjögren's syndrome secondary to RA

• History of any respiratory disease which (in the opinion of the investigator) would compromise subject safety or the ability of the subject to complete the study (e.g. significant interstitial lung disease, such as pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), moderate-severe asthma, bronchiectasis, previous pulmonary alveolar proteinosis (PAP)

• Clinically-significant or unstable (in the opinion of the investigator) persistent cough or dyspnea that is unexplained

• QT interval corrected for heart rate (QTc) >450 milliseconds (msec) or QTc >480 msec for subjects with bundle branch block. The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF)

• Liver function tests: alanine aminotransferase (ALT) >=1.5x upper limit of normal (ULN); aspartate transaminase (AST) >=1.5xULN; alkaline phosphatase and bilirubin

=1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)

• Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment)

• Clinically significant unstable or uncontrolled acute or chronic disease (e.g., cardiovascular including uncompensated congestive cardiac failure New York Heart Association [NYHA] III or IV, myocardial infarction within 12 months, unstable angina pectoris, uncontrolled hypertension, uncontrolled hypercholesterolemia) pulmonary, hematologic, gastrointestinal (including Crohn's Disease or ulcerative colitis), hepatic, renal, neurological, psychiatric, malignancy, endocrinological or infectious diseases, which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk

• A history of malignant neoplasm within the last 10 years or breast cancer within the last 20 years, except for non-melanoma skin cancers that have been excised and cured or carcinoma in situ of the uterine cervix

• Kidney disease: Current or history of renal disease, or estimated creatinine clearance <60 milliliter (mL)/minute (min)/1.73 m2 (MDRD formula) or serum creatinine >1.5xULN within 4 weeks of Day 1

• Hereditary or acquired immunodeficiency disorder, including immunoglobulin deficiency

• History of infected joint prosthesis at any time, with the prosthesis still in situ. History of leg ulcers, catheters, chronic sinusitis or recurrent chest or urinary tract infections

• Active infections, or history of recurrent infections (excluding recurrent fungal infections of the nail bed), or have required management of acute or chronic infections, as follows:

• Currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria)

• OR Hospitalization for treatment of infection within 26 weeks of Day 1

• OR Use of parenteral (Intravenous (IV) or Intramuscular (IM) antimicrobials (antibacterials, antivirals, antifungals, or antiparasitic agents) within 26 weeks of Day 1 or oral antimicrobials within 2 weeks of Day 1

• A vaccination (live or attenuated) within 30 days of Day 1 or Bacillus Calmette-Guérin (BCG) vaccination within 1 year of Day 1, or a live vaccination planned during the course of the study (including follow-up period).

• Any surgical procedure, including bone or joint surgery/synovectomy within 12 weeks prior to Day 1 or any planned surgery within the duration of the study (including follow-up period)

• Use of prohibited medications Prior to AND throughout the study:

Any conventional DMARDs other than MTX (including sulfasalazine, bucillamine, iguratimod, tacrolimus) should be withdrawn at least 2 weeks prior to Day 1.

Subjects may require longer to discontinue azathioprine or leflunomide prior to Day 1:

Azathioprine must be discontinued >=4 weeks prior to randomization; Leflunomide must be discontinued >=12 weeks prior to Day 1 (or >=14 days after 11 days of standard cholestyramine or activated charcoal washout).

• For these subjects, written informed consent for the study must be obtained prior to beginning the screening period. However, other screening assessments, other than consent, must occur within 4 weeks prior to Day 1.

• Any biologic agents (such as Tumor necrosis factor (TNF) inhibitors [including adalimumab, etanercept, infliximab, certolizumab pegol, golimumab] or non-TNF inhibitors [including abatacept, rituximab, tocilizumab, belimumab]).

• Any Janus kinase (JAK) inhibitors (such as tofacitinib).

• Any anti-rheumatic investigational compounds.

• Any alkylating agents (such as cyclophosphamide).

• Plasmapheresis or intravenous immunoglobulin (IVIG) within 26 weeks of Day 1.

Corticosteroids:

• Any Intramascular (IM), Intravenous (IV) or Intra-arterial (IA) corticosteroids within 8 weeks of Day 1.

• Oral corticosteroids:

• Any treatment with >10 mg/day dose oral prednisolone (or equivalent) within 4 weeks of Day 1.

• New oral corticosteroid or changes in corticosteroid dose within the 4 weeks prior to Day 1. (New topical steroids and immunosuppressive agents (e.g., eye drops, creams) are permitted)

• Non-steroidal anti-inflammatory drugs (NSAIDs):

• New or change in dose of NSAID within 2 weeks of Day 1

• Any non-anti-rheumatic investigational treatment must be discontinued for at least 4 weeks or 5 half-lives, whichever is longer, prior to Day 1

• Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within a year prior to Day 1

• History of sensitivity to any of the study treatments, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation

• Abnormal chest X-ray within 12 weeks of Day 1 (locally read and reported by a radiologist) judged by the investigator as clinically-significant

• Any Grade 3 or 4 hematology or clinical chemistry laboratory abnormality, within 4 weeks of Day 1

• Hemoglobin ≤9 g/dL; white blood cell count ≤3.0 x 109/L; platelet count ≤100 x 109/L; absolute neutrophil count ≤1.5 x 109/L; lymphocyte count ≤0.5 x 109/L within 4 weeks of Day 1

• Serologic evidence of current/previous Hepatitis B virus (HBV) infection based on the results of testing for Hepatitis B surface antigen (HBsAg) and anti-Hepatitis B core (anti-HBc) antibody as follows within 4 weeks of Day 1

• Subjects positive for HBsAg and/or positive for anti-HBc antibody (regardless of anti-HBs antibody status) are excluded

• Subjects with positive anti-HBs antibody and HBV-DNA (>=2.1 log copies/mL) are excluded.

• Hepatitis C: Positive test for Hepatitis C virus (HCV) antibody confirmed on a subsequent blood sample by ribonucleic acid - polymerized chain reaction (RNA-PCR) assay within 4 weeks of Day 1.

• Subjects who are positive for Hepatitis C antibody and negative when the Hepatitis C RNA-PCR assay is performed on a subsequent sample will be eligible to participate. Subjects who are positive for Hepatitis C antibody and have a positive result for the HCV when the Hepatitis C RNA-PCR assay is performed on the subsequent sample will not be eligible to participate

• Positive serology for human immunodeficiency virus (HIV) 1 or 2 (within 4 weeks of Day

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	GSK Investigational Site	Aichi		Japan	440-8510
2	GSK Investigational Site	Aichi		Japan	440-85
3	GSK Investigational Site	Aichi		Japan	455-8530
4	GSK Investigational Site	Aichi		Japan	455-85
5	GSK Investigational Site	Aichi		Japan	457-8511
6	GSK Investigational Site	Aichi		Japan	457-85
7	GSK Investigational Site	Chiba		Japan	260-8712
8	GSK Investigational Site	Chiba		Japan	260-87
9	GSK Investigational Site	Chiba		Japan	270-2296
10	GSK Investigational Site	Chiba		Japan	270-22
11	GSK Investigational Site	Fukuoka		Japan	810-8563
12	GSK Investigational Site	Fukuoka		Japan	810-85
13	GSK Investigational Site	Fukuoka		Japan	814-0180
14	GSK Investigational Site	Fukuoka		Japan	814-01
15	GSK Investigational Site	Hyogo		Japan	665-0827
16	GSK Investigational Site	Hyogo		Japan	665-08
17	GSK Investigational Site	Hyogo		Japan	673-1462
18	GSK Investigational Site	Hyogo		Japan	673-14
19	GSK Investigational Site	Ibaraki		Japan	312-0057
20	GSK Investigational Site	Ibaraki		Japan	312-00
21	GSK Investigational Site	Kanagawa		Japan	222-0036
22	GSK Investigational Site	Kanagawa		Japan	240-8521
23	GSK Investigational Site	Kanagawa		Japan	240-85
24	GSK Investigational Site	Kanagawa		Japan	245-8575
25	GSK Investigational Site	Kanagawa		Japan	245-85
26	GSK Investigational Site	Nagasaki		Japan	857-1195
27	GSK Investigational Site	Nagasaki		Japan	857-11
28	GSK Investigational Site	Osaka		Japan	543-8555
29	GSK Investigational Site	Osaka		Japan	543-85
30	GSK Investigational Site	Osaka		Japan	586-8521
31	GSK Investigational Site	Wakayama		Japan	649-2211
32	GSK Investigational Site	Wakayama		Japan	649-22

Sponsors and Collaborators

• GlaxoSmithKline

Investigators

• Study Director: GSK Clinical Trials, GlaxoSmithKline
• Study Director: GSK Clinical Trials, GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

Study Documents (Full-Text)

• Study Protocol - May 19, 2017
• Statistical Analysis Plan - Jan 24, 2018

More Information

Additional Information:

• IPD for this study will be made available via the Clinical Study Data Request site.

Publications

None provided.

• Responsible Party: GlaxoSmithKline
• ClinicalTrials.gov Identifier: NCT03028467
• Other Study ID Numbers: 201789
• First Posted: Jan 23, 2017
• Last Update Posted: Jun 26, 2019
• Last Verified: Apr 1, 2019

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by GlaxoSmithKline: GSK3196165; Active Rheumatoid Arthritis; Methotrexate; Monoclonal Antibody; Efficacy; Electrocardiogram; Tolerability; Pharmacokinetics; Japanese Subjects
• Additional relevant MeSH terms: Arthritis; Arthritis, Rheumatoid; Folic Acid; Methotrexate

Study Results

Participant Flow

Recruitment Details	This study was conducted to assess pharmacokinetics (PK), safety, tolerability and efficacy of GSK3196165 for 12 weeks, in combination with Methotrexate (MTX), in Japanese participants with active moderate-severe rheumatoid arthritis (RA) despite treatment with MTX. Participants were enrolled at 15 centers in Japan from 24-Jan-2017 to 30-Jun-2017.
Pre-assignment Detail	A total of 35 participants were screened, and 20 participants failed screening because of not met eligibility criteria (18 participants) and withdrawal by participant (2 participants). Hence, a total of 15 participants were enrolled and randomized to study treatment.

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Period Title: Overall Study
STARTED	4	3	4	4
COMPLETED	4	3	4	4
NOT COMPLETED	0	0	0	0

Baseline Characteristics

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg	Total
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Total of all reporting groups
Overall Participants	4	3	4	4	15
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]	52.0 (14.45)	58.0 (15.72)	66.5 (2.52)	52.0 (9.20)	57.1 (11.82)
Sex: Female, Male (Count of Participants)
Female	3 75%	2 66.7%	1 25%	3 75%	9 60%
Male	1 25%	1 33.3%	3 75%	1 25%	6 40%
Race/Ethnicity, Customized (Count of Participants)
Japanese/East Asian Heritage (EAH)/South EAH	4 100%	3 100%	4 100%	4 100%	15 100%

Outcome Measures

1. Primary Outcome

Title	Maximum Observed Concentration (Cmax) of GSK3196165
Description	Blood samples were collected at pre-dose on Days 1, 8, 15, 29, 57 and 71; and at any time during visit on Days 3, 74, 85, 106, 127 and 155. PK parameters were calculated by non-compartmental analysis using the concentration data after last dosing (Day 71). Only those participants whose parameters could be determined were analyzed. PK Population included all GSK3196165-treated participants from whom PK samples were collected and analyzed.
Time Frame	Pre-dose on Days 1, 8, 15, 29, 57 and 71; anytime during visit on Days 3, 74, 85, 106, 127 and 155

Outcome Measure Data

Analysis Population Description

PK Population. Only those participants with data available at the specified time points were analyzed.

Arm/Group Title	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	2	3	4
Geometric Mean (95% Confidence Interval) [Nanogram per milliliter (ng/mL)]	699.92	1444.88	3924.10

2. Primary Outcome

Title	Area Under the Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC [0-t]), AUC From Time Zero Extrapolated to Infinity (AUC [0-inf]), AUC Over the Dosing Interval (AUCtau) of GSK3196165
Description	Blood samples were collected at pre-dose on Days 1, 8, 15, 29, 57 and 71; and at any time during visit on Days 3, 74, 85, 106, 127 and 155. PK parameters were calculated by non-compartmental analysis using the concentration data after last dosing (Day 71). NA indicates data was not available as geometric mean and/or 95 percent confidence interval could not be calculated when number of participant was not sufficient.
Time Frame	Pre-dose on Days 1, 8, 15, 29, 57 and 71; anytime during visit on Days 3, 74, 85, 106, 127 and 155

Outcome Measure Data

Analysis Population Description

PK Population. Only those participants whose parameters could be determined were analyzed (represented by n=X in the category titles).

Arm/Group Title	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	3	4	4
AUC (0-t), n=2, 3, 4	189948.606	386497.495	1186604.746
AUC (0-inf), n=0, 1, 2	732243.847	1097422.958
AUCtau, n=1, 3, 4	196562.287	303167.467	787570.414

3. Primary Outcome

Title	Time to Reach Cmax (Tmax) of GSK3196165
Description	Blood samples were collected at pre-dose on Days 1, 8, 15, 29, 57 and 71; and at any time during visit on Days 3, 74, 85, 106, 127 and 155. PK parameters were calculated by non-compartmental analysis using the concentration data after last dosing (Day 71).
Time Frame	Pre-dose on Days 1, 8, 15, 29, 57 and 71; anytime during visit on Days 3, 74, 85, 106, 127 and 155

Outcome Measure Data

Analysis Population Description

PK Population. Only those participants whose parameters could be determined were analyzed.

Arm/Group Title	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	2	3	4
Median (Full Range) [Hour]	48.99167	70.61667	69.80000

4. Primary Outcome

Title	Terminal Half-life (t1/2) of GSK3196165
Description	Blood samples were collected at pre-dose on Days 1, 8, 15, 29, 57 and 71; and at any time during visit on Days 3, 74, 85, 106, 127 and 155. PK parameters were calculated by standard non-compartmental analysis from the concentration data after last dosing (Day 71). NA indicates data was not available as 95 percent confidence interval could not be calculated when number of participant was not sufficient.
Time Frame	Pre-dose on Days 1, 8, 15, 29, 57 and 71; anytime during visit on Days 3, 74, 85, 106, 127 and 155.

Outcome Measure Data

Analysis Population Description

PK Population. Only those participants whose parameters could be determined were analyzed.

Arm/Group Title	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	0	1	2
Geometric Mean (95% Confidence Interval) [Hour]	282.85265	245.12966

5. Primary Outcome

Title	Number of Participants With Any Adverse Event (AE), Serious AE (SAE) and Adverse Events of Special Interest (AESI)
Description	An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or event associated with liver injury and impaired liver function were categorized as SAE. AESI included serious infections including serious respiratory infections and tuberculosis and opportunistic infections, neutropenia (grade 3 or 4), respiratory events, pulmonary alveolar proteinosis, hypersensitivity reactions including anaphylaxis and injection site reactions.
Time Frame	Up to 22 weeks

Outcome Measure Data

Analysis Population Description

Intent-to-Treat (ITT) Population. It included all participants who were randomized to treatment and who received at least one dose of study treatment.

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
Any AE	3 75%	2 66.7%	3 75%	2 50%
Any SAE	1 25%	0 0%	0 0%	0 0%
Any AESI	2 50%	0 0%	1 25%	0 0%

6. Secondary Outcome

Title	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Description	Vital sign measurements including SBP and DBP were measured after 5 minutes rest before each reading. Baseline was considered as the latest pre-dose assessment. The change from Baseline is defined as the difference between the post-dose visit value and Baseline value.
Time Frame	Baseline and up to 22 weeks

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
SBP, Week 1	-0.3 (8.62)	-7.7 (2.89)	-15.0 (17.36)	-1.0 (8.45)
SBP, Week 2	-1.8 (8.34)	-6.7 (12.06)	-4.5 (12.48)	1.5 (1.91)
SBP, Week 3	0.5 (4.80)	-1.7 (12.01)	-10.5 (20.47)	-0.8 (6.02)
SBP, Week 4	-5.8 (10.14)	-11.3 (17.10)	-3.3 (17.88)	6.3 (7.63)
SBP, Week 6	-2.0 (5.66)	-12.7 (11.59)	-1.3 (15.50)	-2.3 (11.62)
SBP, Week 8	-6.3 (7.41)	-3.0 (13.00)	-5.8 (18.55)	3.8 (2.22)
SBP, Week 10	2.3 (4.86)	6.7 (5.03)	-11.8 (23.04)	-1.5 (2.65)
SBP, Week 12	2.0 (11.49)	-5.3 (9.45)	-2.5 (14.29)	0.8 (6.60)
SBP, Follow up (Week 22)	4.0 (13.88)	-4.7 (14.50)	-2.5 (22.52)	-4.3 (3.50)
DBP, Week 1	-1.0 (4.08)	-3.3 (10.97)	-6.8 (6.85)	-0.5 (8.35)
DBP, Week 2	-1.5 (7.33)	0.3 (1.53)	2.0 (5.60)	-0.3 (5.44)
DBP, Week 3	-4.3 (6.95)	-1.0 (6.56)	-5.3 (9.57)	-4.3 (2.75)
DBP, Week 4	-1.0 (7.39)	-1.3 (3.79)	1.3 (7.46)	1.3 (6.60)
DBP, Week 6	-1.0 (8.04)	7.7 (5.77)	5.3 (11.03)	-5.5 (4.12)
DBP, Week 8	-2.5 (3.32)	11.3 (7.02)	-1.5 (10.66)	-2.0 (10.39)
DBP, Week 10	-2.3 (3.59)	2.7 (10.26)	-3.0 (8.83)	-4.5 (3.70)
DBP, Week 12	3.5 (6.24)	-1.7 (4.73)	-3.8 (10.53)	-4.3 (6.40)
DBP, Follow up (Week 22)	2.8 (6.99)	-1.0 (8.72)	3.0 (12.54)	-3.5 (5.26)

7. Secondary Outcome

Title	Change From Baseline in Heart Rate (HR)
Description	Vital sign measurements including HR was measured after 5 minutes rest before each reading. Baseline was considered as the latest pre-dose assessment. The change from Baseline is defined as the difference between the post-dose visit value and Baseline value.
Time Frame	Baseline and up to 22 weeks

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
Week 1	0.3 (5.12)	-8.0 (3.61)	11.5 (13.30)	-0.8 (4.27)
Week 2	3.0 (11.34)	-5.3 (2.31)	9.5 (15.15)	-5.0 (1.41)
Week 3	1.3 (3.59)	-5.3 (3.79)	10.8 (18.10)	-7.0 (5.94)
Week 4	2.5 (5.45)	-5.7 (14.01)	12.0 (15.12)	-7.8 (2.06)
Week 6	7.3 (10.11)	-7.3 (6.43)	11.0 (15.92)	-0.5 (11.50)
Week 8	5.8 (8.26)	-2.7 (10.12)	1.8 (11.30)	-11.5 (6.66)
Week 10	8.3 (9.07)	1.3 (8.02)	0.8 (11.41)	-8.8 (10.94)
Week 12	-2.0 (8.68)	-10.0 (7.00)	12.5 (11.03)	-7.8 (5.56)
Follow up (Week 22)	-2.3 (7.14)	-6.0 (11.53)	6.3 (20.34)	-1.3 (8.22)

8. Secondary Outcome

Title	Change From Baseline in Body Temperature
Description	Vital sign measurements including body temperature was measured after 5 minutes rest before each reading. Baseline was considered as the latest pre-dose assessment. The change from Baseline is defined as the difference between the post-dose visit value and Baseline value.
Time Frame	Baseline and up to 22 weeks

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
Week 1	0.00 (0.469)	-0.20 (0.346)	0.18 (0.287)	0.05 (0.265)
Week 2	0.07 (0.330)	0.03 (0.153)	-0.13 (0.250)	0.22 (0.718)
Week 3	-0.10 (0.476)	-0.30 (0.265)	0.18 (0.359)	0.15 (0.843)
Week 4	-0.20 (0.327)	-0.47 (0.379)	0.20 (0.316)	-0.15 (0.387)
Week 6	-0.03 (0.377)	0.07 (0.404)	-0.10 (0.200)	-0.02 (0.457)
Week 8	-0.20 (0.424)	0.03 (0.503)	-0.07 (0.377)	0.05 (0.332)
Week 10	0.00 (0.337)	0.13 (0.252)	-0.02 (0.386)	0.17 (0.499)
Week 12	-0.07 (0.427)	0.00 (0.458)	-0.25 (0.370)	0.02 (0.670)
Follow up (Week 22)	-0.47 (0.862)	-0.13 (0.208)	0.25 (0.311)	-0.18 (0.171)

9. Secondary Outcome

Title	Change From Baseline in Respiratory Rate
Description	Vital sign measurements including respiratory rate was measured after 5 minutes rest before each reading. Baseline was considered as the latest pre-dose assessment. The change from Baseline is defined as the difference between the post-dose visit value and Baseline value.
Time Frame	Baseline and up to 22 weeks

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
Week 1	-2.0 (1.63)	0.7 (1.15)	-1.0 (1.41)	0.8 (2.22)
Week 2	-0.5 (3.42)	0.0 (0.00)	-1.0 (2.00)	0.3 (1.26)
Week 3	0.3 (3.10)	1.3 (2.31)	0.8 (0.96)	1.5 (3.11)
Week 4	-2.5 (3.42)	-1.7 (2.89)	-0.5 (2.38)	0.3 (1.71)
Week 6	1.5 (5.45)	-1.0 (1.73)	-0.3 (0.96)	2.3 (5.19)
Week 8	-0.3 (2.63)	1.3 (2.31)	-1.3 (0.96)	0.3 (1.71)
Week 10	0.0 (1.63)	-0.7 (1.15)	-2.3 (1.50)	1.0 (3.46)
Week 12	1.0 (1.41)	-0.3 (2.52)	-2.5 (3.11)	0.8 (3.59)
Follow up (Week 22)	0.0 (0.82)	0.3 (3.51)	-1.5 (2.08)	0.5 (1.00)

10. Secondary Outcome

Title	Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
Description	12-Lead ECGs were taken using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and corrected QT (QTc) intervals. Number of participants with any abnormal findings in ECG recordings were summarized as clinically significant and not clinically significant. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time Frame	At Week 12

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
Abnormal - Not clinically significant	1 25%	1 33.3%	1 25%	0 0%
Abnormal - Clinically significant	0 0%	0 0%	0 0%	0 0%

11. Secondary Outcome

Title	Number of Participants With Emergent Hematology Results Relative to Normal Range
Description	Blood samples were collected to evaluate hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), erythrocytes, reticulocytes, white blood cells (WBC), total neutrophils, eosinophils, basophils, monocytes, lymphocytes, platelet count, activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, erythrocyte sedimentation rate (ESR). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose lab value category was unchanged (e.g. High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if they had values that changed 'To Low' and 'To High', so the percentages may not add to 100% in such instances.
Time Frame	Up to 22 weeks

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
APTT, To Low	1 25%	0 0%	1 25%	0 0%
APTT, To Normal or No change	3 75%	3 100%	3 75%	4 100%
APTT, To High	0 0%	0 0%	0 0%	0 0%
Basophils, To Low	0 0%	0 0%	0 0%	0 0%
Basophils, To Normal or No change	4 100%	3 100%	4 100%	4 100%
Basophils, To High	0 0%	0 0%	0 0%	0 0%
Eosinophils, To Low	0 0%	0 0%	0 0%	0 0%
Eosinophils, To Normal or No change	4 100%	3 100%	4 100%	4 100%
Eosinophils, To High	0 0%	0 0%	0 0%	0 0%
ESR, To low	0 0%	0 0%	0 0%	0 0%
ESR, To Normal or No change	2 50%	3 100%	4 100%	4 100%
ESR, To High	2 50%	0 0%	0 0%	0 0%
Fibrinogen, To Low	0 0%	0 0%	0 0%	0 0%
Fibrinogen, To Normal or No change	3 75%	3 100%	4 100%	4 100%
Fibrinogen, To High	1 25%	0 0%	0 0%	0 0%
Hemoglobin, To Low	1 25%	1 33.3%	2 50%	0 0%
Hemoglobin, To Normal or No change	3 75%	2 66.7%	2 50%	4 100%
Hemoglobin, To High	0 0%	0 0%	0 0%	0 0%
Hematocrit, To Low	1 25%	2 66.7%	1 25%	0 0%
Hematocrit, To Normal or No change	3 75%	1 33.3%	3 75%	4 100%
Hematocrit, To High	0 0%	0 0%	0 0%	0 0%
Lymphocytes, To Low	2 50%	1 33.3%	3 75%	0 0%
Lymphocytes, To Normal or No change	2 50%	2 66.7%	1 25%	4 100%
Lymphocytes, To High	0 0%	0 0%	0 0%	0 0%
MCHC, To Low	1 25%	1 33.3%	0 0%	0 0%
MCHC, To Normal or No change	3 75%	2 66.7%	4 100%	4 100%
MCHC, To High	0 0%	0 0%	0 0%	0 0%
MCH, To Low	1 25%	0 0%	0 0%	0 0%
MCH, To Normal or No change	3 75%	3 100%	4 100%	4 100%
MCH, To High	0 0%	0 0%	0 0%	0 0%
MCV, To Low	0 0%	0 0%	0 0%	0 0%
MCV, To Normal or No change	3 75%	3 100%	4 100%	4 100%
MCV, To High	1 25%	0 0%	0 0%	0 0%
Monocytes, To Low	1 25%	0 0%	0 0%	0 0%
Monocytes, To Normal or No change	2 50%	3 100%	4 100%	4 100%
Monocytes, To High	1 25%	0 0%	0 0%	0 0%
Total neutrophils, To Low	0 0%	1 33.3%	0 0%	1 25%
Total neutrophils, To Normal or No change	4 100%	2 66.7%	3 75%	3 75%
Total neutrophils, To High	0 0%	0 0%	1 25%	0 0%
Platelet count, To Low	0 0%	0 0%	0 0%	0 0%
Platelet count, To Normal or No change	4 100%	3 100%	4 100%	4 100%
Platelet count, To High	0 0%	0 0%	0 0%	0 0%
PT, To Low	0 0%	0 0%	0 0%	0 0%
PT, To Normal or No change	4 100%	2 66.7%	4 100%	4 100%
PT, To High	0 0%	1 33.3%	0 0%	0 0%
RBC, To Low	0 0%	0 0%	3 75%	0 0%
RBC, To Normal or No change	4 100%	3 100%	1 25%	4 100%
RBC, To High	0 0%	0 0%	0 0%	0 0%
Reticulocytes, To Low	0 0%	0 0%	0 0%	0 0%
Reticulocytes, To Normal or No change	4 100%	3 100%	4 100%	4 100%
Reticulocytes, To High	0 0%	0 0%	0 0%	0 0%
WBC, To Low	0 0%	0 0%	0 0%	0 0%
WBC, To Normal or No change	4 100%	3 100%	4 100%	3 75%
WBC, To High	0 0%	0 0%	0 0%	1 25%

12. Secondary Outcome

Title	Number of Participants With Emergent Clinical Chemistry Results Relative to Normal Range
Description	Blood samples were collected to evaluate Albumin, Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Total Bilirubin, Calcium, Cholesterol, Creatine Kinase, C-Reactive protein (CRP), Creatinine, Gamma Glutamyl Transferase (GGT), Glucose, High Density Lipids (HDL), Potassium, Lactate Dehydrogenase, Low Density Lipids (LDL), Sodium, Phosphorus inorganic, Triglycerides, Total Protein and Urea. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose lab value category was unchanged (e.g. High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if they had values that changed 'To Low' and 'To High', so the percentages may not add to 100% in such instances.
Time Frame	Up to 22 weeks

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
Albumin, To Low	0 0%	0 0%	2 50%	0 0%
Albumin, To Normal or No change	4 100%	3 100%	2 50%	4 100%
Albumin, To High	0 0%	0 0%	0 0%	0 0%
ALP, To Low	0 0%	0 0%	0 0%	0 0%
ALP, To Normal or No change	2 50%	3 100%	4 100%	4 100%
ALP, To High	2 50%	0 0%	0 0%	0 0%
ALT, To Low	0 0%	0 0%	0 0%	0 0%
ALT, To Normal or No change	4 100%	3 100%	4 100%	4 100%
ALT, To High	0 0%	0 0%	0 0%	0 0%
AST, To Low	0 0%	0 0%	0 0%	0 0%
AST, To Normal or No change	4 100%	3 100%	4 100%	3 75%
AST, To High	0 0%	0 0%	0 0%	1 25%
Total Bilirubin, To Low	2 50%	0 0%	0 0%	0 0%
Total Bilirubin, To Normal or No change	2 50%	3 100%	4 100%	4 100%
Total Bilirubin, To High	0 0%	0 0%	0 0%	0 0%
Calcium, To Low	1 25%	0 0%	1 25%	1 25%
Calcium, To Normal or No change	3 75%	3 100%	3 75%	3 75%
Calcium, To High	0 0%	0 0%	0 0%	0 0%
Cholesterol, To Low	0 0%	0 0%	0 0%	0 0%
Cholesterol, To Normal or No change	2 50%	2 66.7%	4 100%	4 100%
Cholesterol, To High	2 50%	1 33.3%	0 0%	0 0%
Creatine Kinase, To Low	0 0%	1 33.3%	0 0%	0 0%
Creatine Kinase, To Normal or No change	3 75%	2 66.7%	4 100%	3 75%
Creatine Kinase, To High	1 25%	0 0%	0 0%	1 25%
CRP, To Low	0 0%	0 0%	0 0%	0 0%
CRP, To Normal or No change	2 50%	3 100%	4 100%	4 100%
CRP, To High	2 50%	0 0%	0 0%	0 0%
Creatinine, To Low	0 0%	1 33.3%	1 25%	0 0%
Creatinine, To Normal or No change	4 100%	2 66.7%	3 75%	4 100%
Creatinine, To High	0 0%	0 0%	0 0%	0 0%
GGT, To Low	0 0%	0 0%	0 0%	0 0%
GGT, To Normal or No change	4 100%	3 100%	4 100%	4 100%
GGT, To High	0 0%	0 0%	0 0%	0 0%
Glucose, To Low	0 0%	0 0%	0 0%	1 25%
Glucose, To Normal or No change	1 25%	2 66.7%	3 75%	2 50%
Glucose, To High	3 75%	1 33.3%	1 25%	1 25%
HDL, To Low	0 0%	1 33.3%	0 0%	0 0%
HDL, To Normal or No change	4 100%	2 66.7%	4 100%	4 100%
HDL, To High	0 0%	0 0%	0 0%	0 0%
Potassium To Low	2 50%	1 33.3%	1 25%	0 0%
Potassium, To Normal or No change	2 50%	2 66.7%	3 75%	4 100%
Potassium, To High	0 0%	0 0%	0 0%	0 0%
Lactate Dehydrogenase, To Low	0 0%	0 0%	0 0%	0 0%
Lactate Dehydrogenase, To Normal or No change	3 75%	3 100%	3 75%	3 75%
Lactate Dehydrogenase, To High	1 25%	0 0%	1 25%	1 25%
LDL, To Low	0 0%	0 0%	0 0%	0 0%
LDL, To Normal or No change	2 50%	2 66.7%	4 100%	4 100%
LDL, To High	2 50%	1 33.3%	0 0%	0 0%
Sodium, To Low	0 0%	0 0%	0 0%	0 0%
Sodium, To Normal or No change	4 100%	3 100%	4 100%	4 100%
Sodium, To High	0 0%	0 0%	0 0%	0 0%
Phosphorus inorganic, To Low	0 0%	0 0%	0 0%	0 0%
Phosphorus inorganic, To Normal or No change	4 100%	3 100%	4 100%	4 100%
Phosphorus inorganic, To High	0 0%	0 0%	0 0%	0 0%
Triglycerides, To Low	0 0%	0 0%	0 0%	1 25%
Triglycerides, To Normal or No change	4 100%	3 100%	4 100%	3 75%
Triglycerides, To High	0 0%	0 0%	0 0%	0 0%
Total Protein, To Low	1 25%	1 33.3%	1 25%	0 0%
Total Protein, To Normal or No change	3 75%	2 66.7%	3 75%	4 100%
Total Protein, To High	0 0%	0 0%	0 0%	0 0%
Urea, To Low	1 25%	0 0%	0 0%	1 25%
Urea, To Normal or No change	3 75%	3 100%	3 75%	3 75%
Urea, To High	0 0%	0 0%	1 25%	0 0%

13. Secondary Outcome

Title	Number of Participants With Urinalysis Dipstick Findings
Description	Urine samples were collected for analysis of presence of glucose and protein in urine by dipstick method. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine protein and glucose can be read as negative, Trace, 1+, 2+ and 3+, indicating proportional concentrations in the urine sample
Time Frame	Up to 22 weeks

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
Week 4, Glucose, 1+	0 0%	0 0%	0 0%	0 0%
Week 4, Glucose, 2+	0 0%	0 0%	0 0%	0 0%
Week 4, Glucose, 3+	0 0%	0 0%	0 0%	1 25%
Week 4, Glucose, Negative	4 100%	3 100%	4 100%	3 75%
Week 4, Glucose, Trace	0 0%	0 0%	0 0%	0 0%
Week 4, Protein, 1+	1 25%	0 0%	1 25%	0 0%
Week 4, Protein, 2+	0 0%	0 0%	0 0%	0 0%
Week 4, Protein, 3+	0 0%	0 0%	0 0%	0 0%
Week 4, Protein, Negative	1 25%	3 100%	2 50%	4 100%
Week 4, Protein, Trace	2 50%	0 0%	1 25%	0 0%
Week 8, Glucose, 1+	0 0%	0 0%	0 0%	1 25%
Week 8, Glucose, 2+	0 0%	0 0%	0 0%	0 0%
Week 8, Glucose, 3+	0 0%	0 0%	0 0%	0 0%
Week 8, Glucose, Negative	4 100%	3 100%	4 100%	3 75%
Week 8, Glucose, Trace	0 0%	0 0%	0 0%	0 0%
Week 8, Protein, 1+	0 0%	0 0%	1 25%	0 0%
Week 8, Protein, 2+	0 0%	0 0%	0 0%	0 0%
Week 8, Protein, 3+	0 0%	0 0%	0 0%	0 0%
Week 8, Protein, Negative	1 25%	3 100%	3 75%	2 50%
Week 8, Protein, Trace	3 75%	0 0%	0 0%	2 50%
Week 12, Glucose, 1+	0 0%	0 0%	0 0%	0 0%
Week 12, Glucose, 2+	0 0%	0 0%	0 0%	0 0%
Week 12, Glucose, 3+	0 0%	0 0%	0 0%	0 0%
Week 12, Glucose, Negative	4 100%	3 100%	4 100%	4 100%
Week 12, Glucose, Trace	0 0%	0 0%	0 0%	0 0%
Week 12, Protein, 1+	0 0%	0 0%	0 0%	1 25%
Week 12, Protein, 2+	0 0%	0 0%	0 0%	0 0%
Week 12, Protein, 3+	0 0%	0 0%	0 0%	0 0%
Week 12, Protein, Negative	3 75%	3 100%	3 75%	3 75%
Week 12, Protein, Trace	1 25%	0 0%	1 25%	0 0%
Follow up (Week 22), Glucose, 1+	0 0%	0 0%	0 0%	0 0%
Follow up (Week 22), Glucose, 2+	0 0%	0 0%	0 0%	0 0%
Follow up (Week 22), Glucose, 3+	0 0%	0 0%	0 0%	0 0%
Follow up (Week 22), Glucose, Negative	4 100%	3 100%	4 100%	4 100%
Follow up (Week 22), Glucose, Trace	0 0%	0 0%	0 0%	0 0%
Follow up (Week 22), Protein, 1+	1 25%	0 0%	1 25%	0 0%
Follow up (Week 22), Protein, 2+	0 0%	0 0%	0 0%	0 0%
Follow up (Week 22), Protein, 3+	0 0%	0 0%	0 0%	0 0%
Follow up (Week 22), Protein, Negative	2 50%	3 100%	3 75%	3 75%
Follow up (Week 22), Protein, Trace	1 25%	0 0%	0 0%	1 25%

14. Secondary Outcome

Title	Number of Participants With Anti-GSK3196165 Antibody Test Results
Description	Serum samples were collected and tested for presence of antibodies that bind to GSK3196165. The presence of treatment emergent anti-drug antibodies (ADA) were determined using a GSK3196165 bridging style ADA assay with a bio-analytically determined cut point determined during assay validation. Samples taken after dosing with GSK3196165 that have a value at or above the cut-point were considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Baseline was considered as the latest pre-dose assessment. Number of participants with post-Baseline negative or positive anti-GSK3196165 antibody test results were presented.
Time Frame	Weeks 2, 4, 12 and 22

Outcome Measure Data

Analysis Population Description

Immunogenicity Population. The immunogenicity Population included all participants in the ITT Population, who had at least one immunogenicity assessment.

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
Week 2, Positive	0 0%	0 0%	0 0%	0 0%
Week 2, Negative	4 100%	3 100%	4 100%	4 100%
Week 4, Positive	0 0%	0 0%	0 0%	0 0%
Week 4, Negative	4 100%	3 100%	4 100%	4 100%
Week 12, Positive	0 0%	0 0%	0 0%	0 0%
Week 12, Negative	4 100%	3 100%	4 100%	4 100%
Week 22 (Follow up), Positive	0 0%	0 0%	0 0%	0 0%
Week 22 (Follow up), Negative	4 100%	3 100%	4 100%	4 100%

15. Secondary Outcome

Title	Change From Baseline in Disease Activity Score for 28 Different Joints C-reactive Protein (DAS28 [CRP]) at All Indicated Timepoints
Description	DAS28 (CRP) is a measure of disease activity in rheumatoid arthritis obtained by examination of 28 joints for swelling and tenderness using CRP as a blood biomarker for inflammation. Its components include: Tender/Painful Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), CRP and Patient's Global Assessment of Arthritis. DAS28 (CRP) was calculated by 0.56 (square root of TJC28)+ 0.28 (square root of SJC28)+ 0.36 (natural logarithm [CRP+1])+ (0.014*patients global assessment)+0.96. Scores ranges from 0 to infinity, where higher scores indicates high disease activity. Scores higher than 5.1 indicates high disease activity and scores lower than 2.6 indicates remission. Baseline was considered as the latest pre-dose assessment. The change from Baseline is defined as the difference between the post-dose visit value and Baseline value. Adjusted mean and standard error of adjusted mean are presented using Mixed Model for Repeated Measures.
Time Frame	Baseline, up to Week 22

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	Placebo	GSK3196165 45 mg	GSK3196165 90 mg	GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.	Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
Measure Participants	4	3	4	4
Week 1	-0.2179 (0.44925)	-1.3289 (0.51977)	-0.7356 (0.42589)	-0.7511 (0.42569)
Week 2	0.1643 (0.48797)	-0.9744 (0.56457)	-0.7262 (0.46260)	-0.6404 (0.46238)
Week 4	-0.0887 (0.59912)	-1.5462 (0.69316)	-0.9781 (0.56796)	-1.2502 (0.56769)
Week 6	-0.5455 (0.55367)	-0.8664 (0.64058)	-0.7330 (0.52487)	-1.0048 (0.52463)
Week 8	-0.2710 (0.69364)	-0.9231 (0.80253)	-0.8209 (0.65757)	-1.2375 (0.65726)
Week 12	-0.8234 (0.76338)	-1.1810 (0.88321)	-0.6383 (0.72368)	-0.9415 (0.72335)
Week 22 (Follow-up)	-0.3044 (0.62302)	-1.7320 (0.72082)	0.2371 (0.59062)	-1.0976 (0.59035)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 90 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-1.1110
	Confidence Interval	(2-Sided) 95%; -2.7186 to 0.4965
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 1. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.5177
	Confidence Interval	(2-Sided) 95%; -1.9040 to 0.8685
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 1. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.5332
	Confidence Interval	(2-Sided) 95%; -1.9140 to 0.8475
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 1. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 90 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-1.1387
	Confidence Interval	(2-Sided) 95%; -2.8848 to 0.6075
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 2. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.8905
	Confidence Interval	(2-Sided) 95%; -2.3962 to 0.6153
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 2. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.8047
	Confidence Interval	(2-Sided) 95%; -2.3045 to 0.6951
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 2. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 90 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-1.4575
	Confidence Interval	(2-Sided) 95%; -3.6013 to 0.6863
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 4. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.8894
	Confidence Interval	(2-Sided) 95%; -2.7381 to 0.9593
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 4. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-1.1615
	Confidence Interval	(2-Sided) 95%; -3.0028 to 0.6799
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 4. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 90 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.3209
	Confidence Interval	(2-Sided) 95%; -2.3021 to 1.6603
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 6. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.1876
	Confidence Interval	(2-Sided) 95%; -1.8960 to 1.5209
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 6. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.4593
	Confidence Interval	(2-Sided) 95%; -2.1610 to 1.2424
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 6. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 90 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.6521
	Confidence Interval	(2-Sided) 95%; -3.1342 to 1.8300
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 8. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.5499
	Confidence Interval	(2-Sided) 95%; -2.6903 to 1.5904
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 8. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.9665
	Confidence Interval	(2-Sided) 95%; -3.0984 to 1.1654
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 8. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 90 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.3576
	Confidence Interval	(2-Sided) 95%; -3.0892 to 2.3740
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 12. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	0.1851
	Confidence Interval	(2-Sided) 95%; -2.1704 to 2.5407
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 12. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.1181
	Confidence Interval	(2-Sided) 95%; -2.4643 to 2.2281
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 12. The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 90 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-1.4276
	Confidence Interval	(2-Sided) 95%; -3.6569 to 0.8018
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 22 (Follow up). The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	0.5415
	Confidence Interval	(2-Sided) 95%; -1.3810 to 2.4639
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 22 (Follow up). The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	GSK3196165 45 mg, GSK3196165 180 mg
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Net)
	Estimated Value	-0.7932
	Confidence Interval	(2-Sided) 95%; -2.7080 to 1.1217
	Parameter Dispersion	Type: Value:
	Estimation Comments	Week 22 (Follow up). The analysis method was mixed-model for repeated measures with Visit,Treatment group,Visit by Treatment interaction,Baseline DAS28(CRP),and Visit by Baseline DAS28(CRP) interaction as fixed effects.

Adverse Events

Time Frame	Serious adverse events (SAEs) and non-serious adverse events (non-serious AEs) were collected from the start of the study treatment up to Week 22.
Adverse Event Reporting Description	SAEs and non-serious AEs were reported for the ITT Population.
Arm/Group Title	Placebo		GSK3196165 45 mg		GSK3196165 90 mg		GSK3196165 180 mg
Arm/Group Description	Participants received placebo weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.		Participants received GSK3196165 45 milligram (mg) weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.		Participants received GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.		Participants received GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There were 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants also received a stable dose of MTX during the Treatment Period.
All Cause Mortality
	Placebo		GSK3196165 45 mg		GSK3196165 90 mg		GSK3196165 180 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/4 (0%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Serious Adverse Events
	Placebo		GSK3196165 45 mg		GSK3196165 90 mg		GSK3196165 180 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/4 (25%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Respiratory, thoracic and mediastinal disorders
Pleurisy	1/4 (25%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Other (Not Including Serious) Adverse Events
	Placebo		GSK3196165 45 mg		GSK3196165 90 mg		GSK3196165 180 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	3/4 (75%)		2/3 (66.7%)		3/4 (75%)		2/4 (50%)
Eye disorders
Cataract	0/4 (0%)		0/3 (0%)		1/4 (25%)		0/4 (0%)
Conjunctival haemorrhage	0/4 (0%)		0/3 (0%)		1/4 (25%)		0/4 (0%)
Conjunctivitis allergic	0/4 (0%)		1/3 (33.3%)		0/4 (0%)		0/4 (0%)
Gastrointestinal disorders
Dental caries	0/4 (0%)		0/3 (0%)		1/4 (25%)		0/4 (0%)	0
Large intestine polyp	1/4 (25%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Lip oedema	0/4 (0%)		1/3 (33.3%)		0/4 (0%)		0/4 (0%)
Periodontal disease	1/4 (25%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Stomatitis	0/4 (0%)		0/3 (0%)		0/4 (0%)		1/4 (25%)
General disorders
Feeling hot	0/4 (0%)		0/3 (0%)		1/4 (25%)		0/4 (0%)
Infections and infestations
Nasopharyngitis	0/4 (0%)		0/3 (0%)		0/4 (0%)		1/4 (25%)
Oral candidiasis	1/4 (25%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Upper respiratory tract infection	0/4 (0%)		1/3 (33.3%)		0/4 (0%)		0/4 (0%)
Injury, poisoning and procedural complications
Contusion	0/4 (0%)		1/3 (33.3%)		0/4 (0%)		0/4 (0%)
Rib fracture	1/4 (25%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Investigations
Carbon monoxide diffusing capacity decreased	1/4 (25%)		0/3 (0%)		1/4 (25%)		0/4 (0%)
Blood creatine phosphokinase increased	1/4 (25%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Blood lactate dehydrogenase increased	1/4 (25%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Nervous system disorders
Hypoaesthesia	0/4 (0%)		1/3 (33.3%)		0/4 (0%)		0/4 (0%)
Respiratory, thoracic and mediastinal disorders
Cough	1/4 (25%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Oropharyngeal discomfort	1/4 (25%)		0/3 (0%)		0/4 (0%)		0/4 (0%)
Upper respiratory tract inflammation	0/4 (0%)		0/3 (0%)		1/4 (25%)		0/4 (0%)
Skin and subcutaneous tissue disorders
Eczema	0/4 (0%)		0/3 (0%)		1/4 (25%)		0/4 (0%)
Erythema	0/4 (0%)		0/3 (0%)		1/4 (25%)		0/4 (0%)
Haemorrhage subcutaneous	0/4 (0%)		0/3 (0%)		1/4 (25%)		0/4 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.